Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

• Status: Recruiting
• Trial end date: 2028-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yang Li
• Treatments: Arsenic Trioxide

Criteria

Inclusion Criteria:

1. Untreated Stage 4/M neuroblastoma patients according to the International Neuroblastoma Staging System（INSS) or the International Neuroblastoma Risk Group (INRG) staging system;

2. Patients not more than 14 years old;

3. There are measurable lesions;

4. Guardians agreed and signed informed consent.

Exclusion Criteria:

1. Patients who had suffered from other tumors and received chemotherapy or abdominal radiotherapy.

2. Patients with one or more critical organs failure such as heart, brain, kidney failure.